Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026764 (
multiple myeloma
)
36,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Alkyltransferase (
AGT
) repairs alkylation at O6-guanine in DNA and is a major determinant of susceptibility to alkylating chemotherapeutic agents and carcinogens. Using a newly developed flow cytometry assay with the monoclonal anti-
AGT
antibody, mT3.1, we compared
AGT
expression in single-cell suspensions with standard biochemical and Western blot assays to validate the fluorescence-activated cell sorting (FACS) method and develop potential applications. From Chinese hamster ovary cells (CHO) transfected with human O6-methylguanine-DNA methyl-transferase cDNA, 6 CHO-O6-methylguanine-DNA methyl-transferase clones were isolated that expressed 0.3 to 64 fmol/microgram DNA (by biochemical assay) of human
AGT
. FACS yielded a linear relationship between mean fluorescence intensity and both
AGT
activity by biochemical assay and
AGT
protein by Western blot. Using this standard curve, FACS-analyzed
AGT
protein content in human peripheral blood mononuclear cells (PBMCs) from normal donors ranged from 6.1 to 12.8 fmol/microgram DNA, similar to those obtained by biochemical assay and Western blot. This suggests that the level of immunoreactive protein appears to be an accurate predictor of
AGT
activity in the steady state. FACS-
AGT
in PBMCs from normal donors had a low index of heterogeneity within the sample. In contrast, by FACS-
AGT
analysis of human bone marrow samples and granulocyte-colony-stimulating factor-mobilized PBMCs,
AGT
was lower and had an 8-fold higher index of heterogeneity than observed in PBMCs from normal donors. After treatment with O6-benzylguanine (O6-bG), Western and FACS-
AGT
detected significant levels of
AGT
protein for up to 24 h, whereas biochemical assay showed
AGT
activity less than 5% of the basal level. Because only the biochemical assay accurately measures net
AGT
activity, the
AGT
-FACS assay will not be useful in clinical trials to assess the efficacy of O6-bG or other
AGT
inhibitors. Thus,
AGT
-FACS can rapidly assess the heterogeneity of steady-state
AGT
in single-cell suspensions and may be useful for assay in lymphocytes, bone marrow cells, leukemic
myeloma
plasma cells, or cells transfected with the
AGT
gene; Western blot analysis is better for small samples such as tumor biopsies, whereas biochemical assay is best able to measure enzyme activity and its inactivation by O6-bG or other agents.
...
PMID:Heterogeneity of O6-alkylguanine-DNA-alkyltransferase measured by flow cytometric analysis in blood and bone marrow mononuclear cells. 951 39